Selected as one of 20 startups in the inaugural AWS Generative AI accelerator cohort
We are pleased to share that Vevo Therapeutics (Now Tahoe) has been selected to join the AWS Startups Generative AI Accelerator. Only 21 leading startups in the Generative AI space (out of 1200+ companies) were selected to be in the inaugural cohort.
Our team, which already enjoys the support of some of the most esteemed thought leaders in the space (our advisors Richard Socher, Bo Wang, Michael Keiser and co-founders Hani Goodarzi and Kevan Shokat), is excited to join forces with AWS to build new bridges between biology, chemistry, and AI.
We will soon share more about what we have been quietly building: Single-cell Foundation Models that learn the complexities of biological systems. These models allow us to go beyond single target, structure-based drug discovery towards systems biology-based generative drug design.
How are we uniquely positioned to do this? In a single experiment, our Mosaic platform can measure how millions of individual cells from a diverse set of patients interact with drug molecules in organoid and in vivo disease models.
In only a few months, we can gather as much data as is currently available publicly; within a few years, we will accumulate orders of magnitude more.
